Investment Highlights The company announced its 14-year annual report. During the reporting period, the company achieved operating income of 2,772 billion yuan, up 6.38% year on year; operating profit of 305 million yuan, up 24.14% year on year; net profit attributable to owners of the parent company was 197 million yuan, up 26.49% year on year; net profit not attributable to parent company was 171 million yuan, up 14.38% year on year; EPS 0.39 yuan; and cash disbursement of 1.70 yuan for every 10 shares (tax included). The company plans to make use of its comparative advantages and simultaneously build two profit platforms for pharmaceutical production and marketing and medical services. It strives to make the profit levels of the two main businesses go hand in hand through 3-5 years of efforts. The company's development in the field of medical services deserves long-term attention. We expect the company's EPS for 2015-2017 to be 0.48, 0.57, and 0.65 yuan respectively, corresponding valuations of 37, 31, and 27 times. For the first time, the company was given an “increase in holdings” rating.